BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30952619)

  • 21. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
    Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
    Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population.
    Tantengco OAG; Nakura Y; Yoshimura M; Llamas-Clark EF; Yanagihara I
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):2103-2107. PubMed ID: 31350972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
    Loi S; Michiels S; Lambrechts D; Fumagalli D; Claes B; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Piccart MJ; Joensuu H; Sotiriou C
    J Natl Cancer Inst; 2013 Jul; 105(13):960-7. PubMed ID: 23739063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
    Xiang L; Jiang W; Li J; Shen X; Yang W; Yang G; Wu X; Yang H
    Sci Rep; 2015 Sep; 5():14035. PubMed ID: 26358014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
    Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
    Luen SJ; Asher R; Lee CK; Savas P; Kammler R; Dell'Orto P; Biasi OM; Demanse D; JeBailey L; Dolan S; Hackl W; Thuerlimann B; Viale G; Colleoni M; Regan MM; Loi S
    JAMA Oncol; 2018 Oct; 4(10):1335-1343. PubMed ID: 29902286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study.
    Halle MK; Ojesina AI; Engerud H; Woie K; Tangen IL; Holst F; Høivik E; Kusonmano K; Haldorsen IS; Vintermyr OK; Trovik J; Bertelsen BI; Salvesen HB; Krakstad C
    Am J Obstet Gynecol; 2017 Oct; 217(4):432.e1-432.e17. PubMed ID: 28599900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
    De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
    Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
    Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW
    Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
    Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program.
    Hou MM; Liu X; Wheler J; Naing A; Hong D; Bodurka D; Schmeler K; Tsimberidou A; Janku F; Zinner R; Piha-Paul S; Hu CY; Lu K; Kurzrock R; Fu S
    Anticancer Res; 2014 May; 34(5):2349-55. PubMed ID: 24778042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
    Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
    Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Holst F; Werner HMJ; Mjøs S; Hoivik EA; Kusonmano K; Wik E; Berg A; Birkeland E; Gibson WJ; Halle MK; Trovik J; Cherniack AD; Kalland KH; Mills GB; Singer CF; Krakstad C; Beroukhim R; Salvesen HB
    Clin Cancer Res; 2019 Jan; 25(1):334-345. PubMed ID: 30442683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.
    Kim SI; Cho JH; Seol A; Kim YI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Gynecol Oncol; 2019 Apr; 153(1):3-12. PubMed ID: 30642625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic alterations and PIK3CA gene mutations and amplifications analysis in cervical cancer by racial groups in the United States.
    Femi OF
    Int J Health Sci (Qassim); 2018; 12(1):28-32. PubMed ID: 29623014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
    Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
    Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
    Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
    BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.